As legislators consider policy and regulatory options to lower the cost of prescription drugs, the American College of Rheumatology (ACR) is calling for an end to step therapy (or sometimes called “fail first” policies) as well as the switching of medications in stable patients purely for cost reasons.
As legislators consider policy and regulatory options to lower the cost of prescription drugs, the American College of Rheumatology (ACR) is calling for an end to step therapy (or sometimes called “fail first” policies) as well as the switching of medications in stable patients purely for cost reasons.
Non-medical switching in a stable patient among branded products and across therapeutic classes without the consent of the patient and the provider is inappropriate and potentially harmful, the ACR says.
“We continue to emphasize these topics because they are so critical to the well-being of millions of Americans living with rheumatic diseases, some of which can be quite debilitating and even lead to death,” says Colin Edgerton, MD, a rheumatologist at Low Country Rheumatology in South Carolina and chair of the ACR’s Committee on Rheumatologic Care, in a statement. “The need for patients to have access to prompt, affordable, and medically necessary treatments is ongoing and should be considered at every step of the policy making process.”
The statement comes as several bills regarding prescription prices, as well as making biosimilars more accessible, have been introduced in Congress.
One of these bills, the Medicare Negotiation and Competitive Licensing Act, would allow the HHS secretary to negotiate prices for Medicare Part D drugs directly. Another, while not directly targeting prices, aims at unraveling the patent thickets that prevent biosimilars from coming to market.
On the regulatory side, CMS is allowing the use of step therapy in Medicare Advantage plans.
The ACR’s position statement on drug pricing asks for:
ACR’s step therapy statement asks that pharmacy review committees include rheumatologists to help develop formulary benefits programs.
“Step therapy has resulted in forced drug switching, treatment gaps, and cessation of effective therapy,” the statement says. “In addition to the dangers to the patient related to loss of access to therapy and disease flares, these programs may result in immunogenicity, adverse effects, and secondary nonresponse. Downstream effects of restricted access can lead to complications such as uncontrolled disease for the patient, disabilities, and increased health care costs.”
Last year, the ACR released its first-ever Rheumatic Disease Report Card, which shows the burden of rheumatic disease in each state. The average state grade was a “C.”
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.